![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 23, 17869-17877, June 9, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of
Received for publication, January 11, 2000, and in revised form, March 8, 2000
Sialic acids participate in many important
biological recognition events, yet eukaryotic sialic acid biosynthetic
genes are not well characterized. In this study, we have identified a
novel human gene based on homology to the Escherichia coli
sialic acid synthase gene (neuB). The human gene is
ubiquitously expressed and encodes a 40-kDa enzyme. The gene partially
restores sialic acid synthase activity in a neuB-negative
mutant of E. coli and results in
N-acetylneuraminic acid (Neu5Ac) and
2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN) production in insect cells upon recombinant baculovirus infection. In vitro the human enzyme uses
N-acetylmannosamine 6-phosphate and mannose 6-phosphate as
substrates to generate phosphorylated forms of Neu5Ac and KDN,
respectively, but exhibits much higher activity toward the Neu5Ac
phosphate product.
The sialic acids are a family of nine carbon 2-keto-3-deoxy sugars
found in viruses, bacteria, and many higher animals, including humans
(1). Sialic acids are frequently the terminal sugars on secreted and
cell surface glycoproteins and glycolipids, and their presence can have
considerable influence on the biological properties of a cell. For
example, the temporal appearance and disappearance of polysialic
polymers has been intimately linked with the proper development of
neural tissues during embryogenesis (2, 3). In pathogenic diseases,
including meningitis and gastric inflammation, particular microbes
recognize cell surface sialic acids when invading host cells (1).
Sialic acid residues can also mask recognition sites (4) such as
galactose residues on glycoproteins to prevent their in vivo
removal by asialoglycoprotein receptors (5). In certain cancers,
changes in sialic acid amounts, types, and linkages have been
associated with tumorogenesis and cancer metastasis (6, 7).
The biological significance of sialic acids underscores the importance
of characterizing their biosynthetic pathways. Multiple sialic acid
synthetic and degradative pathways have been identified in bacteria and
eukaryotes (Fig. 1). Sialic acid aldolase
is found in both bacteria and mammals and reversibly forms
N-acetylneuraminic acid
(Neu5Ac)1 from pyruvate and
N-acetylmannosamine (ManNAc) in a reaction favoring ManNAc
(8). The Escherichia coli sialic acid synthase gene
(neuB), which has been cloned and characterized, encodes an
enzyme that directly converts phosphoenolpyruvate (PEP) and ManNAc to
Neu5Ac (9), the most common sialic acid. Corfield et al.
(10) attempted to find a similar sialic acid synthase activity in
mammalian cells but found only the products of the pathway involving
phosphate intermediates. This three-enzyme pathway converts ManNAc to
Neu5Ac through the intermediates N-acetylmannosamine 6-phosphate (ManNAc-6-P) and N-acetylneuraminate 9-phosphate
(11-13). The initial phosphorylation step is carried out by a recently cloned bifunctional enzyme that converts
UDP-N-acetylglucosamine to ManNAc-6-P (14). None of the
subsequent genes involved in Neu5Ac synthesis in eukaryotes have
previously been identified.
For sialylation to occur, Neu5Ac is then converted to the activated
nucleotide sugar, cytidine monophosphate Neu5Ac (CMP-Neu5Ac) by
CMP-Neu5Ac synthase. Genes for this enzyme have been identified in both
prokaryotes (15) and eukaryotes (16). Sialyltransferases then use the
sugar nucleotide as the substrate for sialylation of glycoconjugates.
In addition to Neu5Ac, over 40 other naturally occurring varieties of
sialic acid have been identified in biological systems (17). Deaminated
Neu5Ac
(2-keto-3-deoxy-D-glycero-D-galacto-nononic acid; KDN), was discovered in 1986 in fish eggs and has since been
observed in different species ranging from lower vertebrates to mammals
(18). Less is known about KDN synthesis than Neu5Ac synthesis, although
recent enzymatic studies in fish indicate that mannose (Man) and PEP
are the substrates (17). KDN is produced through a multienzyme pathway
involving phosphate intermediates similar to those of the mammalian
Neu5Ac synthesis pathway (19).
In order to identify genes involved in sialic acid biosynthesis in
eukaryotes, homology searches of a human expressed sequence tag (EST)
data base were performed using the E. coli sialic acid synthase gene. A cDNA of approximately 1 kilobase pair with a predicted open reading frame (ORF) of 359 amino acids was identified. Northern blot analysis indicated that the mRNA is ubiquitously expressed, and in vitro transcription and translation along
with recombinant expression in insect cells demonstrated that the gene (SAS) encoded a 40-kDa protein. SAS rescued an
E. coli neuB mutant although less efficiently than
neuB. Neu5Ac production in insect culture supplemented with
ManNAc further supported the role of SAS in sialic acid
biosynthesis. In addition to Neu5Ac, a second sialic acid, KDN, was
generated, suggesting that the human enzyme has broad substrate
specificity. The human enzyme (SAS), unlike its E. coli
homologue, uses phosphorylated substrates to generate phosphorylated
sialic acids and thus probably represents the previously described
sialic acid-9-phosphate synthase of mammalian cells (12).
Gene Characterization--
The E. coli neuB coding
sequence was used to query the Human Genome Sciences (Rockville, MD)
cDNA data base with BLAST software. One EST clone, HMKAK61, from a
human (liver) cDNA library demonstrated significant homology to
neuB and was chosen for further characterization. The tissue
distribution profile was determined by Northern blot hybridization.
Briefly, the cDNA was radiolabeled with [32P]dCTP
using a RediPrimeTMII kit (Amersham Pharmacia Biotech)
following the manufacturer's directions. Multiple tissue Northern
blots containing poly(A)+ RNA
(CLONTECH, Palo Alto, CA) were prehybridized at
42 °C for 4 h and then hybridized overnight with radiolabeled
probe at 1 × 106 cpm/ml. The blots were sequentially
washed twice for 15 min at 42 °C and once for 20 min at 65 °C in
0.1× SSC, 0.1% SDS and subsequently autoradiographed.
Baculovirus Cloning and Protein Expression--
The full-length
ORF was amplified by PCR using the following primers. The
forward primer,
5'-TGTAATACGACTCACTATAGGGCGGATCCGCCATCATGCCGCTGGAGCTGGAGC, contained a synthetic T7 promoter sequence (underlined), a
BamHI site (italic type), a Kozak sequence (boldface type),
and sequence corresponding to the first six codons of SAS.
The minus strand primer,
5'-GTACGGTACCTTATTAAGACTTGATTTTTTTGCC,
contained an Asp718 site (italic type), two in-frame stop codons
(underlined), and sequences representing the last six codons of
SAS.
After amplification, the PCR product was digested with BamHI
and Asp718 (Roche Molecular Biochemicals), and the resulting fragment was cloned into the corresponding sites of the baculovirus transfer vector, pA2. Following DNA sequence confirmation, the plasmid
(pA2-SAS) was transfected into Sf-9 cells to generate the recombinant
baculovirus AcSAS as described previously (20). Amplified virus was
used to infect cells, and the gene product was radiolabeled with
[35S]Met and [35S]Cys. Bands corresponding
to the gene product were visualized by SDS polyacrylamide gel
electrophoresis and autoradiography. Alternatively, the PCR product was
used as a template for in vitro transcription and
translation using rabbit reticulocyte lysate (Promega, Madison, WI) in
the presence of [35S]Met. Translation products were
resolved by SDS-polyacrylamide gel electrophoresis and visualized by autoradiography.
For protein production, Sf-9 cells were seeded in serum-free medium at
a density of 1 × 106 cells/ml in spinner flasks and
infected at a multiplicity of infection of 1-2 with the recombinant
virus. A detergent fractionation procedure was employed to separate
nuclear from nonnuclear fractions (21). Protein was resolved by
SDS-polyacrylamide gel electrophoresis, transferred to a
ProBlottTM membrane (ABI, Foster City, CA), and visualized
by Ponceau S staining. A prominent band at the expected molecular mass
of ~40 kDa was visible and excised for protein microsequencing using an ABI-494 sequencer (PE Biosystems, Foster City, CA).
Prokaryotic Cloning and Purification--
The human sialic acid
synthase gene was transferred to the prokaryotic expression vector
pTrcHis2-TOPO (Invitrogen, Carlsbad, CA). The gene was amplified by PCR
with the forward primer 5'-ATGCCGCTGGAGCTGGAGTGTC, the reverse primer
5'-AGACTTGATTTTTTTGCCATGATTA, and the template pA2-SAS. The PCR product
was ligated into pTrcHis2-TOPO directly, and the resulting plasmid
(pTrcHis2-SAS) was transformed into DH5
The strain DH5 Neu5Ac/KDN Detection--
Sialic acid was measured by the
procedure of Hara et al. (22). Ten µl of sample was
treated with 200 µl of 1,2-diamino-4,5-methylene dioxybenzene
dihydrochloride (DMB; Sigma) solution (7.0 mM DMB in 1.4 M acetic acid, 0.75 M Cell Culture and Sialic Acid Quantification--
Sf-9 (ATCC,
Manassas, VA) cells were grown in Ex-CellTM 405 medium (JRH BioScience, Lenexa, KS) with and without 10% fetal bovine serum (FBS) at 27 °C. CHO-K1 cells (ATCC) were cultured at
37 °C in a humidified atmosphere with 5% CO2 in
Dulbecco's modified Eagle's medium (Life Technologies, Inc.)
supplemented with 10% FBS, 100 units/ml penicillin, 100 µg/ml
streptomycin, 100 µM minimal essential medium essential
amino acids, and 4 mM L-glutamine (Life Technologies). Cells were grown to confluency in T-75 flasks, washed
twice with phosphate-buffered saline, and lysed in 0.05 M
bicine, pH 8.5, with 1 mM dithiothreitol (9) using a Tekmar Sonic Disrupter (Cincinnati, OH). For determination of sialic acid
content, 10 µl of lysates with and without 10,000 molecular weight
cut-off microfiltration (Millipore, Bedford, MA) were analyzed by DMB
derivatization as described above.
Sugar substrate feeding was studied by plating approximately
106 Sf-9 cells on each well of a six-well plate. Medium was
replaced with 2 ml of fresh medium supplemented with 10 mM
sterile-filtered Man, mannosamine (ManN), or ManNAc. Cells were left
uninfected or infected with 20 µl of the appropriate (A35 or AcSAS)
amplified baculovirus stock. Cells were harvested at 80 h
postinfection by separating the pellet from the medium by
centrifugation and washing twice with phosphate-buffered saline. Cells
were lysed and analyzed for sialic acid content as described above.
In Vitro Activity--
In vitro activity assays were
based on the procedure of Angata et al. (19). Lysates were
prepared from A35 and AcSAS infected and uninfected Sf-9 cells cultured
in T-75 flasks. After washing twice with phosphate-buffered saline,
cells were lysed on ice with 25 strokes of a tightly fitting Dounce
homogenizer (Wheaton, Millville, NJ) in 2.5 ml of lysis buffer (50 mM HEPES, pH 7.0, with 1 mM dithiothreitol,
leupeptin (1 µg/ml), antipain (0.5 µg/ml), benzamidine-HCl (15.6 µg/ml), aprotinin (0.5 µg/ml), chymostatin (0.5 µg/ml), and 1 mM phenylmethylsulfonyl fluoride). 5 µl of substrate
solution was incubated with either 20 µl of insect cell lysate (30 min) or purified E. coli protein (60 min) at 37 °C. The
substrate solution contained 10 mM MnCl2, 20 mM PEP, and either 5 mM ManNAc-6-P or 25 mM mannose 6-phosphate (Man-6-P; Sigma). ManNAc-6-P was
prepared by acid hydrolysis of meningococcal group A polysaccharide.
The polysaccharide (15.5 mg) in 5.8 ml of water was mixed with 770 mg
of Dowex 50 H+ and heated for 1 h at 100 °C. The filtered
hydrolysate was dried in vacuo, and the residue was
dissolved to give a solution of 50 mM ManNAc-6-P and stored frozen. Substrate solutions containing 25 mM Man and ManNAc
were also used. Assays performed with boiled lysates or without sugar substrates were used as negative controls. Following incubation, all
samples were boiled for 3 min, centrifuged for 10 min at 12,000 × g, and split into two 10-µl aliquots. One aliquot was
treated with 9 units of calf intestine alkaline phosphatase (Roche
Molecular Biochemicals) along with 3 µl of accompanying buffer, while
the other aliquot was diluted with water and buffer. Alkaline
phosphatase (AP)-treated aliquots were incubated for 4 h at
37 °C, and 10 µl of both AP-treated and -untreated samples were
reacted with DMB as described above. 2 µl of the samples incubated
with insect lysates were injected onto the HPLC for sialic acid
analysis as described above.
Similarly, sialic acid synthase activity in Ni-Superflow-purified
fractions was assayed by the addition of aliquots to a solution containing the substrate mixture (buffer A plus 250 mM
imidazole, pH 8.0) for 1 h at 37 °C. The reaction mixture was
treated with AP, and 10 µl of the resulting sample was analyzed as
described above.
For substrate competition experiments, Man-6-P and ManNAc-6-P
concentrations in the substrate solution were varied from 1 to 20 mM. In vitro assays were run with Sf-9 lysates
as described above. Samples were treated with 7 µl of buffer and 18 units of AP, incubated for 4 h at 37 °C, and analyzed for
sialic acid content. Samples containing more than 1 mM
ManNAc-6-P in the substrate solution produced high levels of sialic
acid and were diluted 1:5 before injection to avoid fluorescence
detector signal saturation.
Phage Sensitivity Assay for Sialic Acid Synthesis--
Sialic
acid synthesis potential for plasmids was assayed by their ability to
restore sensitivity to a polysialic acid specific phage (K1F) of a
sialic acid synthase-negative K1 strain, EV24 (23). Cells harboring the
test plasmid were cross-streaked onto agar plates containing Davis
minimal medium supplemented with casamino acids, 0.2% glucose, 0.1%
yeast extract dialysate, 0.5 mM
isopropyl-1-thio- Analysis with Aldolase Using High Performance Anion Exchange
Chromatography (HPAEC)--
Sf-9 cells were grown in T-75 flasks and
then infected with A35 or AcSAS or left uninfected in the presence or
absence of 10 mM ManNAc. After 80 h, cells were washed
twice in phosphate-buffered saline and sonicated. Aliquots (200 µl)
were filtered through 10,000 molecular weight cut-off membranes, and
50-µl samples were treated with 12.5 µl of aldolase solution
(0.0055 units of aldolase (ICN, Costa Mesa, CA), 1.4 mM
NADH (Sigma), 0.5 M HEPES, pH 7.5, 0.7 units of lactate
dehydrogenase (Roche Molecular Biochemicals)) or left untreated and
incubated at 37 °C for 1 h (24). Samples were analyzed by HPAEC
with a Dionex (Sunnyvale, CA) BioLC system using a pulsed amperometric
detector (PAD-II) on a Carbopac PA-1 column. The initial elution
composition was 50% A (200 mM NaOH), 45% B (water), and
5% C (1 M NaOAc, 200 mM NaOH) with a linear gradient to 50% A, 25% B, and 25% C at 20 min. A 6-min 50% A and 50% C washing followed. Samples were normalized based on protein content by dilution with water, and 20 µl of each sample was
analyzed. Ten µl of each sample was also derivatized with DMB and
analyzed by HPLC as described above to confirm the elimination of
sialic acids by aldolase treatment.
Identification of a Human Sialic Acid Synthase Gene--
The
E. coli sialic acid synthase gene (25) was used to search
the human EST data base of Human Genome Sciences, Inc. (Rockville, MD).
One EST with significant homology to the neuB gene was found in a human liver cDNA library and used to identify a full-length cDNA with an ORF homologous to the bacterial synthase over most of
its length. The putative synthase consisted of 359 amino acids, while
the neuB gene product contained 346 amino acids. Alignment of the human against the bacterial enzyme demonstrated that significant differences were found primarily in the N terminus (Fig.
2). Overall, the two synthases were found
to be 36.1% identical and 56.1% similar at the amino acid level.
The product of a cDNA amplification with a T7 promoter was
expressed by in vitro transcription and translation using
rabbit reticulocyte lysates. The generation of an ~40-kDa protein,
consistent with a predicted molecular mass of 40.3 kDa, confirmed the
existence of an ORF (Fig. 3A,
lane 2). The negative control, namely the vector
without an insert, did not produce a protein product (Fig. 3A, lane 1). Northern blot analysis
was performed on poly(A)+ RNA blots representing a
selection of human tissues (Fig. 3B). The full-length
cDNA was radiolabeled and used as probe. A band of the expected
size, ~1.3 kilobase pairs, was observed in all tissues tested,
suggesting that the putative synthase is ubiquitously expressed.
SAS Is Expressed in Insect Cells and Bacteria--
SAS was
inserted into baculovirus under the polh promoter using
lacZ as a positive selection marker. After transfection and viral titering, the resulting virus (AcSAS) was used to infect Spodoptera frugiperda (Sf-9) cells followed by pulse
labeling. An ~40-kDa band was observed in the Sf-9 lysates from cells
infected by AcSAS (Fig. 3A, lane 5)
and not in the mock-infected control (Fig. 3A,
lane 4). Furthermore, this band co-migrated with
the protein produced in vitro. To verify SAS expression, the
band was visualized in the nonnuclear fraction (21) after
electrophoretic transfer to a ProBlottTM membrane and
Ponceau S staining (data not shown) and excised for amino acid
sequencing. The five N-terminal amino acids were identical to the
second through sixth amino acids of the predicted protein (data not
shown). Interestingly, the initiator methionine was also removed from
the purified recombinant E. coli sialic acid synthase
(9).
SAS was cloned into the prokaryotic expression vector
pTrcHis2 to facilitate purification and to confirm function in
vivo and in vitro. The expressed protein contained a
carboxyl-terminal hexahistidine tag and a Myc peptide epitope. The
chimeric protein was purified using the hexahistidine tag and was
identified by Western blotting (Fig. 3C). N-terminal amino
acid sequencing of the protein band produced in E. coli was
as predicted and also lacked the amino-terminal methionine (data not shown).
SAS Expression Causes in Vivo KDN and Neu5Ac Production in Insect
Cells--
Covalent labeling of sialic acids with the fluorescent
reagent DMB allows very specific and sensitive sialic acid detection (22, 26). The DMB reaction products are identified after separation by
reverse phase HPLC. Using this technique, sialic acid standards were
measured in quantities as low as 50 fmol (data not shown). Sialic acid
levels of an insect cell line (Sf-9) and a mammalian cell line (Chinese
hamster ovary (CHO)) were compared (Table
I). The sialic acid content in cell
lysates before and after filtration through a 10,000 molecular weight
cut-off membrane was determined by DMB labeling and HPLC separation.
The native sialic acid levels in Sf-9 cells grown without FBS
supplementation are substantially lower than the levels found in CHO
cells (Table I; Fig. 4A). To
ensure that the low sialic acid content was not due to the absence of
serum, the sialic acid content of insect cells cultured in 10% FBS was
determined. Even with FBS addition, the Neu5Ac content of Sf-9 cells is
nearly an order of magnitude lower than the content of CHO cells (Table
I). The origin of the sialic acid detected in insect cells, whether
natively produced or the result of contamination from the medium, is
not clear, since even serum-free insect cell medium contains
significant levels of sialic acid (data not shown).
The lack of large sialic acid pools in Sf-9 cells grown in serum-free
medium facilitated the detection of sialic acids produced by
recombinant enzymes. In order to examine the production of sialic acids
from cells infected with recombinant virus, Sf-9 cells were infected
with AcSAS and a negative control virus, A35. The A35 virus was
generated by recombining a transfer vector without a gene inserted
downstream of the polh promoter. Very low levels of Neu5Ac
were observed in lysates from insect cells infected by either virus
(Fig. 4B), indicating that additional Neu5Ac was not
produced following the expression of SAS. However, a significant new
peak was seen in AcSAS lysates at 12.5 min that was not observed in A35
negative control lysates (Fig. 4B). Published chromatograms suggested that the unknown early eluting peak could be
N-glycolylneuraminic acid or KDN (17). The elution time of
the unknown peak was the same as DMB-derivatized KDN standard (Fig.
4B) and co-chromatographed with authentic DMB-KDN (data not
shown), confirming KDN generation in AcSAS-infected Sf-9 cells. KDN was
not detected in uninfected Sf-9 cells either with or without FBS
supplementation (Table I).
In a further attempt to demonstrate Neu5Ac synthetic
functionality, the culture medium was supplemented with ManNAc,
the metabolic precursor of Neu5Ac. In addition to a DMB-KDN peak,
a prominent peak eluting at 17.5 min corresponding with that of the
Neu5Ac standard was observed from the lysates of ManNAc-supplemented Sf-9 cells infected with AcSAS (Fig. 4C). Neu5Ac quantities
were more than 100 times lower in the uninfected lysates and even less in A35-infected lysates (Table II).
Sialic acid levels were quantified in lysates of uninfected,
A35-infected, and AcSAS-infected Sf-9 cells grown in medium with and
without Man, ManN, or ManNAc supplementation (Table II). In uninfected
cells, Man feeding resulted in detection of KDN slightly above
background, and ManNAc feeding marginally increased Neu5Ac levels in
uninfected and A35-infected cells (Table II). ManN supplementation had
no effect on KDN levels but increased Neu5Ac levels (Table II). The
most significant changes in sialic acid levels occurred with AcSAS
infection. AcSAS infection of Sf-9 cells led to large increases in KDN
levels with slight enhancements upon Man or ManNAc supplementation.
Both AcSAS infection and ManNAc feeding were required to obtain
substantial Neu5Ac levels.
The presence of KDN and Neu5Ac in AcSAS lysates has been confirmed by
HPAEC with a pulsed amperometric detector (Fig. 4D). When
the culture medium was supplemented with ManNAc, peaks with elution
times corresponding to authentic KDN and Neu5Ac standards were seen in
AcSAS-infected lysates that were absent in A35-infected lysates. Neu5Ac
aldolase has been demonstrated previously to break Neu5Ac into ManNAc
and pyruvic acid (8) and KDN into Man and pyruvic acid (27). KDN and
Neu5Ac disappeared from the AcSAS lysates after aldolase treatment
(Fig. 4D). A similar disappearance of the sialic acid peaks
following aldolase treatment was observed using DMB labeling and HPLC
analysis (data not shown).
Complementation of Sialic Acid Synthase Negative E. coli K1 with
SAS--
E. coli K1 produces an extracellular polysialic
acid, and this extracellular polysialic acid is detectable by either
specific antibody or infectivity with a polysialic acid-specific
bacteriophage (23). Sialic acid synthase encoded by the neuB
gene is required for the production of polysialic acid. This
prokaryotic indicator system and a mutant with an inactive
neuB gene were used to test SAS function. The
pTrcHis2-SAS plasmid containing SAS was transformed into the
E. coli neuB mutant EV24 (28). Transformants of EV24 E. coli were streaked onto minimal medium plates and
cross-streaked on a perpendicular axis with the polysialic
acid-specific bacteriophage. Growth of EV24 without transformation
was not affected by the bacteriophage streak (Fig.
5, Streaks 1), but
the positive control bacteria, EV36, containing neuB (28)
has significantly reduced growth (Fig. 5, Streaks
2). The infectivity of the EV24 mutant was restored by the
presence of SAS (Fig. 5, Streaks 3) as
evident from the lack of growth in the region streaked with
bacteriophage. However, the plasmid containing SAS did not
appear to complement EV24 as well as a plasmid containing the
prokaryotic neuB gene (Fig. 5, Streaks
4). Similar complementation results were obtained when
restoration of polysialic acid-specific infectivity was measured by
lysis in liquid culture (data not shown). Thus, these experiments indicate that SAS complements the deleted neuB
gene but less efficiently than the native E. coli sialic
acid synthase gene.
SAS Activity Uses Phosphate Intermediates in Vitro--
The
mammalian pathway for Neu5Ac synthesis uses a phosphate intermediate
(11-13), while the E. coli pathway directly converts ManNAc
and PEP to Neu5Ac (9). In order to determine which substrates are used
by the human enzyme, in vitro assays were performed using lysates of infected Sf-9 cells and protein purified from the
prokaryotic expression system. Lysates or purified protein plus PEP and
MnCl2 (19) were incubated with Man, Man-6-P, ManNAc, or
ManNAc-6-P followed by DMB labeling and HPLC analysis.
AcSAS-infected cell lysates incubated with ManNAc-6-P and PEP produced
a peak eluting at 5.5 min (Fig.
6A), consistent with phosphorylated sugars. In previous studies, phosphorylated KDN was
detected as DMB-KDN after AP treatment and DMB derivatization (19).
Similarly, the peak eluting at 5.5 min was exchanged for one that
eluted at the same time as authentic Neu5Ac following AP treatment
(Fig. 6A). Likewise, an early eluting peak from the incubation mixture containing Man-6-P yielded a KDN peak after AP
treatment (Fig. 6B). No sialic acid products were detected when A35-infected cell lysates were used in the equivalent assays (data
not shown). In vitro assays were also performed on the
recombinant human synthase purified from E. coli with
similar results. KDN and Neu5Ac peaks were detected when Man-6-P and
ManNAc-6-P were used as substrates, respectively, followed by AP
treatment (Fig. 6C). Assays performed using ManNAc and Man
as substrates were compared with those using ManNAc-6-P and Man-6-P
after AP treatment. Upon AP treatment, Neu5Ac production with 5 mM ManNAc-6-P as the substrate was 70 times the Neu5Ac
production obtained using 25 mM ManNAc as a substrate (Fig.
7A). When Man was used as a
substrate, KDN levels did not increase above the background levels of
KDN obtained from an AcSAS infection (Fig. 7B). Sialic acid
peaks were also not observed when Man or ManNAc was used as a substrate in assays with the human synthase purified from E. coli
(data not shown).
Assays were performed by incubating lysates with different substrate
solution concentrations of Man-6-P and ManNAc-6-P in order to evaluate
substrate preference. After incubation for a fixed time period, the
samples were treated with AP, and DMB derivatives of Neu5Ac and KDN
were quantified and compared (Table III).
When equimolar amounts of substrates are used, Neu5Ac production is significantly favored over KDN especially at higher equimolar concentrations (10 and 20 mM) of the two substrates. Only
when the substrate concentration of ManNAc-6-P is substantially lower than the Man-6-P levels are production levels of the two sialic acids
comparable. When the ManNAc-6-P concentration is 1 mM and the Man-6-P level is 20 mM, the Neu5Ac/KDN production ratio
approaches unity. Therefore, the enzyme prefers ManNAc-6-P over Man-6-P
in the production of phosphorylated forms of Neu5Ac and KDN,
respectively.
We have identified the sequence of a human sialic acid phosphate
synthase gene, SAS, whose protein product condenses
ManNAc-6-P or Man-6-P with PEP to form Neu5Ac and KDN phosphates,
respectively. To our knowledge, this is the first report of the cloning
of a eukaryotic sialic acid phosphate synthase gene. Despite the
importance of sialic acids in many biological recognition phenomena,
sialic acid phosphate synthase genes have not been cloned because the enzymes they encode are unstable and difficult to purify (12, 19). Even
the E. coli sialic acid synthase enzyme, whose sequence is
known, has low specific activity and is unstable (9).
Consequently, a bioinformatics approach based on the E. coli
synthase sequence was used to identify a putative human gene 36%
identical and 56% similar to neuB. In vitro transcription and translation verified an open reading frame that encoded a 359-amino
acid protein. In addition, Northern blots revealed ubiquitous transcription of the human synthase gene in a selection of human tissues. The wide distribution of SAS mRNA is consistent with the
detection of sialic acids in many different mammalian tissues (18).
Using the baculovirus expression system, the 40-kDa sialic acid
phosphate synthase enzyme, SAS, was expressed in cells. The use of Sf-9
cells that have little if any native sialic acid greatly facilitated
the detection of sialic acids and the characterization of SAS. However,
Neu5Ac was observed only when insect cells were infected with AcSAS and
the cell culture medium was supplemented with ManNAc, a sialic acid
precursor. This ManNAc feeding requirement indicates that Sf-9 cells
may lack sizable ManNAc pools and synthetic pathways.
SAS was identified based on homology with neuB, whose enzyme
product directly forms Neu5Ac from ManNAc and PEP (9). The E. coli sialic acid synthase has previously shown no sialic acid synthetic activity with ManNAc-6-P or Man as substrate (9). However,
mammalian cells are known only to produce Neu5Ac from ManNAc through a
three-step pathway with phosphorylated intermediates. Therefore,
in vitro assays were performed to determine the substrate specificity of SAS. Assays with AcSAS-infected Sf-9 lysates using ManNAc-6-P showed 70 times the sialic acid levels of those using ManNAc
even when ManNAc was supplied at 5 times the ManNAc-6-P concentration.
The synthesis of small amounts of Neu5Ac using ManNAc as a substrate
may result either from low level conversion of the ManNAc substrate or
from insect cell hexokinase activity in the cell lysates. Hexokinases
could convert ManNAc supplied in the assay and ATP, which exists in
substantial quantities in AcSAS-infected insect cells (data not shown),
to ManNAc-6-P.
The product of the ManNAc-6-P reaction was further characterized. A
rapidly eluting DMB-derivatized product, typical of a phosphorylated
sialic acid, was observed when ManNAc-6-P was used as the substrate.
Furthermore, this peak disappeared with the appearance of an
unsubstituted DMB-Neu5Ac peak following AP treatment. SAS therefore
condenses PEP and ManNAc-6-P to form a Neu5Ac phosphate product.
Although the exact position of the phosphorylated carbon on the product
has not yet been specified, SAS is probably the sialic acid phosphate
synthase enzyme of the previously described three-step mammalian
pathway (11-13). Despite the presence of few if any native pools of
sialic acids, Sf-9 cells possess the ability to complete the three-step
mammalian pathway when only the sialic acid phosphate synthase gene is
provided. Sf-9 cells have been shown to have significant ManNAc kinase
ability (29), and phosphatase activity has also been detected in insect
cells (30).
The capacity to produce sialic acids in Sf-9 cells following AcSAS
infection and ManNAc supplementation at levels even higher than those
seen in a mammalian cell line such as CHO may help overcome a major
limitation of the baculovirus expression system. N-Glycans
of recombinant glycoproteins produced in insect cells lack significant
levels of terminal sialic acid residues (31, 32). The lack of
sialylation on human thyrotropin produced by the baculovirus expression
system resulted in rapid in vivo thyrotropin clearance as
compared with thyrotropin produced by a mammalian system (5).
Generation of significant sialic acid pools along with expression of
other genes such as sialyltransferases may lead to production of
significant levels of sialylated glycoproteins in insect cells.
Differences in substrate specificity between the human and E. coli synthase enzymes may explain the limited effectiveness of
neuB recovery with SAS in E. coli.
Partial complementation of the E. coli EV24 neuB
mutant with SAS suggests that either ManNAc may be a low
level substrate or sialic acid is formed through the action of an
intracellular phosphatase. In the latter case, ManNAc-6-P would be
converted to phosphorylated sialic acid by SAS with subsequent
conversion to sialic acid. Since the amount of complementation observed
is low, high levels of endogenous phosphatase activity or ManNAc-6-P
are not required. ManNAc-6-P can be generated in bacteria by
N-acyl-D-glucosamine 6-phosphate 2-epimerase,
which converts N-acetylglucosamine 6-phosphate to ManNAc-6-P
(33). Differences in protein folding between the E. coli and
human enzymes may also contribute to the inability of SAS to
completely recover neuB function in bacteria. SAS expressed in E. coli also included a C-terminal histidine tag and Myc
epitope, whose effects on SAS activity are unknown.
Another interesting observation was the occurrence of a second
DMB-reactive peak in AcSAS-infected Sf-9 lysates. This peak has been
identified as KDN, a deaminated Neu5Ac. We subsequently demonstrated
that the SAS enzyme generates KDN phosphate from Man-6-P and PEP
in vitro, and no KDN synthetic ability is detected using Man
as a substrate. While Neu5Ac production in insect cells requires both
AcSAS infection and ManNAc supplementation, only AcSAS infection is
necessary for KDN synthesis. Therefore, significant substrate pools for
the generation of KDN already exist in insect cells or are present in
the medium. In addition, mannose feeding increased KDN production even
further. Interestingly, Man feeding of the uninfected insect cells
increased KDN levels above background, and ManNAc feeding also led to
higher Neu5Ac levels in uninfected cells. Therefore, insect cells may
possess limited native sialic acid synthetic ability. Similar substrate
supplementation results have been reported in mammalian cells, since
cultivation in Man-rich or ManNAc-rich medium enhanced the synthesis of
native intracellular KDN and Neu5Ac, respectively (34).
This study is the first report of a eukaryotic gene encoding any enzyme
with KDN synthetic ability. Recently, KDN enzymatic activity has been
characterized in trout testis, a tissue high in KDN content. KDN is
synthesized from Man in trout through a three-step pathway involving a
synthase with a Man-6-P substrate (19). However, the fish synthase
enzyme, partially purified from trout testis, was approximately 80 kDa
as compared with the human enzyme of 40 kDa. Furthermore, KDN and
Neu5Ac phosphate synthesis in trout were probably catalyzed by two
separate synthase activities (19), while the current study indicates
that both products were generated from a single human enzyme with broad substrate specificity.
Neu5Ac, usually bound to glycoconjugates, is the predominant sialic
acid found in mammalian tissue, but KDN, primarily found free in the
ethanol-soluble fractions, has also been detected in all human tissues
examined so far (18). The ratio of Neu5Ac to KDN is on the order of
100:1 in blood cells and ovaries (17), although this ratio may change
during development and cancer. The levels of free KDN in newborn fetal
cord red blood cells are higher than those of maternal red blood cells
(17). Furthermore, a 4.2-fold increase in the ratio of free KDN to free
Neu5Ac was observed in ovarian tumor cells as compared with normal
cells, and the ratio appears to increase with the extent of invasion or
malignancy for ovarian adenocarcinomas (17).
Because the KDN/Neu5Ac ratio has biological significance, we performed
competitive in vitro assays with insect cell lysates using
both ManNAc-6-P and Man-6-P as substrates. SAS demonstrated a
preference for phosphorylated Neu5Ac over phosphorylated KDN synthesis
in vitro, although the concentrations of the particular substrates relative to the enzyme level altered this production ratio.
Thus, changes in the ratios of free KDN to Neu5Ac observed in different
developmental states and cancer tissue may reflect variability either
in the levels of specific substrates or the amount of active enzyme
present in vivo. The identification of the SAS
genetic sequence and characterization of the enzyme it encodes should
help further our understanding of sialic acid biosynthesis as well as
the roles sialic acids play in development and disease states.
We gratefully thank Eric Vimr for the EV24
E. coli strain and review of the manuscript, Saul Roseman
for review of the manuscript, and Joelle Porter for work on the
Northern blots.
*
This work was supported by National Science Foundation Grant
BES9814100 from the Metabolic Engineering Program and National Science
Foundation Grant DGE9843635 from the Graduate Research Fellowship
Program (to S. M. L.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF257466.
**
To whom correspondence should be addressed: Dept. of Chemical
Engineering, The Johns Hopkins University, Baltimore, MD 21218. Tel.:
410-516-5461; Fax: 410-516-5510; E-mail: beten@jhu.edu.
Published, JBC Papers in Press, April 3, 2000, DOI 10.1074/jbc.M000217200
The abbreviations used are:
Neu5Ac, N-acetylneuraminic acid;
KDN, 2-keto-3-deoxy-D-glycero-D-galacto-nononic
acid;
PEP, phosphoenolpyruvate;
ManNAc, N-acetylmannosamine;
ManNAc-6-P, N-acetylmannosamine 6-phosphate;
CMP-Neu5Ac, cytidine monophosphate Neu5Ac;
Man, mannose;
EST, expressed sequence
tag;
ORF, open reading frame;
DMB, 1,2-diamino-4,5-methylene
dioxybenzene dihydrochloride;
CHO, Chinese hamster ovary;
FBS, fetal
bovine serum;
ManN, mannosamine;
HPAEC, high performance anion exchange
chromatography;
Man-6-P, mannose-6-phosphate;
AP, alkaline phosphatase;
PCR, polymerase chain reaction;
HPLC, high performance liquid
chromatography.
Cloning and Expression of the Human
N-Acetylneuraminic Acid Phosphate Synthase Gene with
2-Keto-3-deoxy-D-glycero- D-galacto-nononic
Acid Biosynthetic Ability*
,
,
,
**
Chemical Engineering and
¶ Biology, The Johns Hopkins University, Baltimore, Maryland
21218, § Protein Development, Human Genome Sciences,
Rockville, Maryland 20850, and
Laboratory of Bacterial Toxins
and Laboratory of Bacterial Polysaccharides, Food and Drug
Administration, Bethesda, Maryland 20892
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (22K):
[in a new window]
Fig. 1.
Bacterial and mammalian sialic acid metabolic
pathways.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
.
:pTrcHis2-SAS was grown in 1.5 liters of LB broth with
100 µg/ml ampicillin until A600 = 0.6. Expression was induced by the addition of 0.5 mM
isopropyl-1-thio-
-D-galactopyranoside for 1 h,
after which the culture was harvested by centrifugation and lysed in a
French pressure cell. The lysate was centrifuged at 27,000 × g for 15 min, and the supernatant was tumbled with Ni-Superflow resin (Qiagen, Valencia, CA) in 50 mM Tris,
300 mM NaCl, pH 8.0 (buffer A) at 6-8 °C overnight. The
suspension was poured into a 0.4 × 4-cm column, and the packed
resin was washed with buffer A and then buffer A plus 20 mM
imidazole until the absorbance at 280 nm returned to base line. The
enzyme was eluted as a single peak with buffer A plus 250 mM imidazole. Enzyme fractions were analyzed by
SDS-polyacrylamide gel electrophoresis and detected in an immunoblot of
these gels using an anti-Myc mouse monoclonal antibody (Invitrogen,
Carlsbad, CA).
-mercaptoethanol, and
18 mM sodium hydrosulfite) at 50 °C for 2.5 h, from
which 10 µl was used for HPLC analysis on a Shimadzu (Columbia, MD)
VP series HPLC using a Waters (Milford, MA) Spherisorb 5-µm ODS2
column. Peaks were detected using a Shimadzu RF-10AXL fluorescence
detector with 448-nm emission and 373-nm excitation wavelengths. The
mobile phase was an acetonitrile, methanol, and water mixture (9:7:84, v/v/v) with a flow rate of 0.7 ml/min. Response factors of Neu5Ac and
KDN were established with authentic standards based on peak areas for
quantifying sample sialic acid levels. Sialic acid content was
normalized based on protein content measured with the Pierce BCA assay
kit and a Molecular Devices (Sunnyvale, CA) microplate reader.
-D-galactopyranoside, and 100 µg/ml
ampicillin. Diminished cell growth was observed in the region of the
culture containing bacteriophage in positive cultures.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (48K):
[in a new window]
Fig. 2.
SAS homology alignment. Amino
acid homology is shown of SAS (top) and bacterial sialic
acid synthase (bottom).

View larger version (61K):
[in a new window]
Fig. 3.
SAS gene products.
A, autoradiogram of SAS gene products after gel
electrophoresis. Lanes labeled In Vitro represent
transcription and translation of PCR product. PCR was performed with
primers as described under "Experimental Procedures" with a T7
promoter using pA2 plasmid as PCR template (lane
1, negative control) and pA2-SAS as PCR template
(lane 2). Lanes labeled Pulse
Label indicate 35S pulse labeling of
A35-infected (lane 4, negative control) and
AcSAS-infected (lane 5) Sf-9 whole cell lysates.
An arrow indicates SAS products. B, Northern blot
probing for SAS mRNA from the indicated human tissues.
PBL, peripheral blood lymphocyte. Scale is given in
kilobases. C, Western blot with anti-Myc mouse monoclonal
antibody of DH5
:pTrcHis2-SAS whole cell lysates (lane
1) and SAS chimeric protein purified by hexahistidine
affinity (lane 2).
Sialic acid content of CHO and Sf-9 cell lines

View larger version (35K):
[in a new window]
Fig. 4.
In vivo sialic acid
content. A, sialic acid content of indicated lysed
cells after filtration through a 10,000 molecular weight cut-off
membrane as measured by DMB derivatization with reverse phase HPLC
separation. The original chromatogram values have been divided by
protein concentration to normalize chromatograms. The Neu5Ac standard
represents 1000 fmol, N-glycolylneuraminic acid
(Neu5Gc) 200 fmol, and KDN 50 fmol. B, sialic
acid content of lysates of Sf-9 cells infected as labeled and grown in
unsupplemented medium as measured by DMB derivatization with reverse
phase HPLC separation. Original chromatogram values have been divided
by protein concentration to normalize chromatograms. Neu5Ac and KDN
standards represent 1000 fmol. C, sialic acid content of
lysates of Sf-9 cells infected as labeled and grown in medium
supplemented with 10 mM ManNAc as measured by DMB
derivatization with reverse phase HPLC separation. Original
chromatogram values have been divided by protein concentrations to
normalize chromatograms. Neu5Ac and KDN standards represent 1000 fmol.
D, HPAEC analysis of lysates of Sf-9 cells supplemented with
10 mM ManNAc and infected with A35 or AcSAS with and
without aldolase treatment as indicated. Samples were diluted prior to
column loading to normalize sialic acid quantities based on original
sample protein concentration. The Neu5Ac standard represents 250 pmol,
and the KDN standard represents 100 pmol.
Sialic acid content of Sf-9 with medium supplementation

View larger version (62K):
[in a new window]
Fig. 5.
NeuB mutant recovery. E. coli
streaks were grown on minimum agar plates containing polysialic acid
recognizing bacteriophage K1F in the plate region perpendicular to
the streaks labeled Infected Region. Streaks were
done from left to right as indicated.
Streaks 1 represent the EV24 mutant harboring a
defective copy of neuB, whereas Streaks
2 are the wild type (phage K1F-sensitive control strain,
EV36). Streaks 3 are EV24 transformed with
pTrcHis2-SAS that expresses chimeric SAS, and
Streaks 4 are EV24 transformed with pNEUB (9)
that expresses neuB.

View larger version (24K):
[in a new window]
Fig. 6.
In vitro assays. Lysates of
Sf-9 cells infected with AcSAS or recombinant protein purified from
E. coli were incubated with Man-6-P or ManNAc-6-P as
described under "Experimental Procedures." A, in
vitro Neu5Ac phosphate synthase assay of Sf-9 lysates before and
after AP treatment with standards (5000 fmol of KDN and Neu5Ac).
B, in vitro KDN phosphate synthase assay of Sf-9
lysates before and after AP treatment with standards (5000 fmol of KDN
and Neu5Ac). C, in vitro assays with ManNAc-6-P
or Man-6-P substrates as indicated using protein samples purified from
E. coli. Samples were treated with AP, and standards
represent 1000 fmol of Neu5Ac and 250 fmol of KDN. The
asterisk indicates a peak caused by a contaminant from the
ManNAc-6-P preparation.

View larger version (15K):
[in a new window]
Fig. 7.
In vitro sugar specificity
assays. Lysates of Sf-9 cells infected with AcSAS were incubated
with Man, ManNAc, Man-6-P, or ManNAc-6-P as described under
"Experimental Procedures." Samples were then analyzed by HPLC after
AP treatment along with standards (2000 fmol of KDN and Neu5Ac).
A, assay with ManNAc-6-P and ManNAc used as sugar
substrates. B, assay with Man-6-P and Man used as sugar
substrates. Background KDN level from AcSAS infection is illustrated by
the chromatogram labeled No Substrate.
Competitive formation of Neu5Ac and KDN
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Schauer, R.,
Kelm, S.,
Reuter, G.,
Roggentin, P.,
and Shaw, L.
(1995)
in
Biology of the Sialic Acids
(Rosenberg, A., ed)
, pp. 7-67, Plenum Press, New York
2.
Cunningham, B. A.,
Hoffman, S.,
Rutishauser, U.,
Hemperly, J. J.,
and Edelman, G. M.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
3116-3120
3.
Hoffman, S.,
and Edelman, G. M.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
5762-5766
4.
Schauer, R.
(1985)
Trends Biochem. Sci.
10,
357-360
5.
Grossmann, M.,
Wong, R.,
Teh, N. G.,
Tropea, J. E.,
East-Palmer, J.,
Weintraub, B. D.,
and Szkudlinski, M. W.
(1997)
Endocrinology
138,
92-100
6.
Fukuda, M.
(1996)
Cancer Res.
56,
2237-2244
7.
Takano, R.,
Muchmore, E.,
and Dennis, J. W.
(1994)
Glycobiology
4,
665-674
8.
Comb, D. G.,
and Roseman, S.
(1960)
J. Biol. Chem.
235,
2529-2537
9.
Vann, W. F.,
Tavarez, J. J.,
Crowley, J.,
Vimr, E.,
and Silver, R. P.
(1997)
Glycobiology
7,
697-701
10.
Corfield, A. P.,
Clamp, J. R.,
and Wagner, S. A.
(1985)
Biochem. J.
226,
163-174
11.
Kundig, W.,
Ghosh, S.,
and Roseman, S.
(1966)
J. Biol. Chem.
241,
5619-5626
12.
Watson, D. R.,
Jourdian, G. W.,
and Roseman, S.
(1966)
J. Biol. Chem.
241,
5627-5636
13.
Jourdian, G. W.,
Swanson, A. L.,
Watson, D.,
and Roseman, S.
(1964)
J. Biol. Chem.
239,
2714-2716
14.
Stasche, R.,
Hinderlich, S.,
Weise, C.,
Effertz, K.,
Lucka, L.,
Moormann, P.,
and Reutter, W.
(1997)
J. Biol. Chem.
272,
24319-24324
15.
Zapata, G.,
Vann, W. F.,
Aaronson, W.,
Lewis, M. S.,
and Moos, M.
(1989)
J. Biol. Chem.
264,
14769-14774
16.
Munster, A. K.,
Eckhardt, M.,
Potvin, B.,
Muhlenhoff, M.,
Stanley, P.,
and Gerardy-Schahn, R.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9140-9145
17.
Inoue, S.,
Lin, S.-L.,
Chang, T.,
Wu, S.-H.,
Yao, C.-W.,
Chu, T.-Y.,
Troy, F. A., II,
and Inoue, Y.
(1998)
J. Biol. Chem.
273,
27199-27204
18.
Inoue, S.,
and Inoue, Y.
(1999)
in
Sialobiology and Other Novel Forms of Glycosylation
(Inoue, Y.
, Lee, Y. C.
, and Troy II, F. A., eds)
, pp. 57-67, Gakushin Publishing Co., Osaka, Japan
19.
Angata, T.,
Nakata, D.,
Matsuda, T.,
Kitajima, K.,
and Troy, F. A., II
(1999)
J. Biol. Chem.
274,
22949-22956
20.
Coleman, T. A.,
Parmelee, D.,
Thotakura, N. R.,
Nguyen, N.,
Burgin, M.,
Gentz, S.,
and Gentz, R.
(1997)
Gene (Amst.)
190,
163-171
21.
Miyamoto, C.,
Smith, G. E.,
Farrell-Towt, J.,
Chizzonite, R.,
Summers, M. D.,
and Ju, G.
(1985)
Mol. Cell. Biol.
5,
2860-2865
22.
Hara, S.,
Yamaguchi, M.,
Takemori, Y.,
Furuhata, K.,
Ogura, H.,
and Nakamura, M.
(1989)
Anal. Biochem.
179,
162-166
23.
Vimr, E. R.
(1992)
J. Bacteriol.
174,
6191-6197
24.
Lilley, G. G.,
von Itzstein, M.,
and Ivancic, N.
(1992)
Protein Expression Purif.
3,
434-440
25.
Annunziato, P. W.,
Wright, L. F.,
Vann, W. F.,
and Silver, R. P.
(1995)
J. Bacteriol.
177,
312-319
26.
Manzi, A. E.,
Diaz, S.,
and Varki, A.
(1990)
Anal. Biochem.
188,
20-32
27.
Nadano, D.,
Iwasaki, M.,
Endo, S.,
Kitajima, K.,
Inoue, S.,
and Inoue, Y.
(1986)
J. Biol. Chem.
261,
11550-11557
28.
Vimr, E. R.,
and Troy, F. A.
(1985)
J. Bacteriol.
164,
854-860
29.
Effertz, K.,
Hinderlich, S.,
and Reutter, W.
(1999)
J. Biol. Chem.
274,
28771-28778
30.
Sukhanova, M.,
Ankilova, I. A.,
Gruntenko, N. E.,
Khlebodarova, T. M.,
Kaidanov, L. Z.,
and Rauscenbach, I.
(1998)
Genetika
34,
1239-1242
31.
Jarvis, D. L.,
and Finn, E. E.
(1995)
Virology
212,
500-511
32.
Ogonah, O. W.,
Freeman, R. B.,
Jenkins, N.,
Patel, K.,
and Rooney, B. C.
(1996)
Bio/Technology
14,
197-202
33.
Ghosh, S.,
and Roseman, S.
(1965)
J. Biol. Chem.
240,
1525-1530
34.
Angata, T.,
Nakata, D.,
Matsuda, T.,
and Kitajima, K.
(1999)
Biochem. Biophys. Res. Commun.
261,
326-331
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. Castilho, M. Pabst, R. Leonard, C. Veit, F. Altmann, L. Mach, J. Glossl, R. Strasser, and H. Steinkellner Construction of a Functional CMP-Sialic Acid Biosynthesis Pathway in Arabidopsis Plant Physiology, May 1, 2008; 147(1): 331 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Viswanathan, N. Tomiya, J. Park, S. Singh, Y. C. Lee, K. Palter, and M. J. Betenbaugh Expression of a Functional Drosophila melanogaster CMP-sialic Acid Synthetase: DIFFERENTIAL LOCALIZATION OF THE DROSOPHILA AND HUMAN ENZYMES J. Biol. Chem., June 9, 2006; 281(23): 15929 - 15940. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hamada, Y. Ito, T. Abe, F. Hayashi, P. Guntert, M. Inoue, T. Kigawa, T. Terada, M. Shirouzu, M. Yoshida, et al. Solution structure of the antifreeze-like domain of human sialic acid synthase Protein Sci., May 1, 2006; 15(5): 1010 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Maliekal, D. Vertommen, G. Delpierre, and E. Van Schaftingen Identification of the sequence encoding N-acetylneuraminate-9-phosphate phosphatase Glycobiology, February 1, 2006; 16(2): 165 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Kim, S.-G. Sampathkumar, M. B. Jones, J. K. Rhee, G. Baskaran, S. Goon, and K. J. Yarema Characterization of the Metabolic Flux and Apoptotic Effects of O-Hydroxyl- and N-Acyl-modified N-Acetylmannosamine Analogs in Jurkat Cells J. Biol. Chem., April 30, 2004; 279(18): 18342 - 18352. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hong and P. Stanley Lec3 Chinese Hamster Ovary Mutants Lack UDP-N-acetylglucosamine 2-Epimerase Activity Because of Mutations in the Epimerase Domain of the Gne Gene J. Biol. Chem., December 26, 2003; 278(52): 53045 - 53054. [Abstract] [Full Text] [PDF] |
||||